2 DECEMBER 2004

NEW ZEALAND GAZETTE, No. 158

3925

in fresh water, for customary food gathering purposes from
within the whole or any part of the area/rohe moana. No
customary food gathering of fisheries resources may take
place in the area/rohe moana without an authorisation from a
Kaitiaki.

Dated at Dunedin this 29th day of November 2004.
ROSE GRINDLEY, Senior Fisheries Management Advisor,
Ministry of Fisheries.

go8062

Health

Human Assisted Reproductive Technology

Act 2004

Approval of Auditing Agency

Pursuant to section 77 (4) of the Human Assisted Reproductive Technology Act 2004, the Director-General of
Health approves the Reproductive Technology Accreditation
Committee (“the auditing agency”) to audit the provision or
likely future provision of the following kinds of health care
services:

• Fertility services

This approval is not subject to any conditions.

Under section 77 (6) of the Human Assisted Reproductive
Technology Act 2004, this approval will expire immediately
before the commencement of the first notice under section
13 of the Health and Disability Services (Safety) Act that
approves standards for fertility services.

Dated at Wellington this 23rd day of November 2004.
K. O. POUTASI (DR), Director-General of Health.

go7925

Medicines Act 1981

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or
use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product: Clozaril
Active Ingredient: Clozapine 100mg
Dosage Form: Tablet
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom

Note: This consent is given subject to the following conditions:

• Clozapine may only be prescribed by:
  – medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of
  psychological medicine or psychiatry; and
  – medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision
  of persons of the kind referred to above.

• Persons prescribing clozapine must comply with the requirements of the New Zealand Guidelines for the Use of Atypical
  Anti-Psychotic Drugs (Second Edition September 1998) and the requirements of local hospital and health service protocols
  for use of clozapine.

Note: This consent is valid for two years from 4 February 2005.

Product: Clozaril
Active Ingredient: Clozapine 25mg
Dosage Form: Tablet
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom

Note: This consent is given subject to the following conditions:

• Clozapine may only be prescribed by:
  – medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of
  psychological medicine or psychiatry; and
  – medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision
  of persons of the kind referred to above.\n
• Persons prescribing clozapine must comply with the requirements of the New Zealand Guidelines for the Use of Atypical
  Anti-Psychotic Drugs (Second Edition September 1998), and the requirements of local hospital and health service protocols
  for the use of clozapine.

Note: This consent is valid for two years from 4 February 2005.

Dated this 26th day of November 2004.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go8013